Therefore, given that SOCS3 is a downstream mediator of IL-6 signaling, studies aiming to determine whether the increased levels of this cytokine in AD elicits insulin signaling impairment via SOCS3 are warranted. The gene discussed is SOCS3; the disease is Alzheimer disease.